A major breakthrough in developing a new therapy for advanced bladder cancer — for which there have been no major treatment advances in the past 30 years — has been made by scientists. The study examined an antibody (MPDL3280A) which blocks a protein (PD-L1) thought to help cancer cells evade immune detection.